OCUMENSION-B News

Okanvision Bio-B (01477.HK): 2023 results meet expectations and expect recent R&D milestones

中金公司Mar 25 16:46

Okanvision Bio-B (01477.HK): OT-703 Hong Kong received the first dose after being approved by Youshiying Health Insurance

中金公司Jan 23 00:00

Okanvision Bio-B (01477.HK): OT-401 successfully included in health insurance and is expected to be released later

中金公司Dec 14, 2023 00:00

Okonvision Bio-B (01477.HK): OT-101 completes global enrollment and continues to increase its commercial layout

中金公司Aug 26, 2023 00:00

Okanvision Bio-B (01477.HK): Comprehensive layout of ophthalmic drug platform-based enterprises to accelerate growth

東方證券Apr 21, 2023 14:38

Okanvision Biology-B (01477.HK) 2022 Annual Report Review: Commercialization is developing rapidly, R&D pipelines are advancing rapidly

興業證券Apr 13, 2023 12:56

Okanvision Bio-B (01477.HK): R&D pipelines gradually reap commercialization channels continue to expand

中金公司Apr 3, 2023 00:00

Changes in Hong Kong stocks | Okanvision Bio-B rose more than 9% last year's revenue and gross profit forecast doubled, Goldman Sachs raised its target price

Gelonghui FinanceFeb 20, 2023 14:19

Okanvision Bio-B (01477.HK): Operating losses continue to narrow and ophthalmology BIOPHARAM grows rapidly

興業證券Sep 1, 2022 00:00

Okanvision Bio-B (01477.HK): 1H22 revenue slightly exceeded our expectations OT-401 approved for listing

中金公司Aug 28, 2022 00:00

Oconvision Bio-B (01477.HK): The core product OT-401 has been approved for listing and the pipeline is gradually being enriched

中金公司Jun 22, 2022 00:00

Okanvision Bio-B (01477.HK): Ophthalmic Pharma construction accelerates OT-401 is expected to be approved soon

興業證券Mar 28, 2022 00:00

Okanvision Bio-B (01477.HK): The results for the first half of 2021 are in line with expectations, and the pipeline is progressing smoothly

中金公司Aug 22, 2021 00:00

Okanvision Bio-B (01477.HK): A number of projects progressed positively in the first half of the year, and the first core product is expected to be launched within the year

興業證券Aug 22, 2021 00:00

Okanvision Bio-B (1477.HK): Focus on ophthalmology medication platforms, core products are about to be harvested

中金公司Jun 23, 2021 00:00

Okanvision Bio-B (01477.HK): Successful introduction of ILUVIEN ophthalmic drug layout to the next level

興業證券Apr 16, 2021 00:00

Okanvision Bio-B (01477.HK): R&D is steadily advancing, and the ophthalmology platform is beginning to take shape

興業證券Mar 23, 2021 00:00

Okanvision Bio-B (1477.HK): Internal R&D and external introduction of a two-wheel strategy create a leading edge in ophthalmology pipelines

興業證券Nov 2, 2020 00:00

When Hong Kong stocks are new, when is the best time to sell them?

東吳證券Oct 28, 2020 09:53

Okanvision Biotech (01477.HK): IPO Report

中泰國際Jun 29, 2020 00:00